IRADIMED shareholders gained a total return of 26% during the year. But that was short of the market average. On the bright side, that's still a gain, and it's actually better than the average return of 20% over half a decade This could indicate that the company is winning over new investors, as it pursues its strategy. It's always interesting to track share price performance over the longer term. But to understand IRADIMED better, we need to consider many other factors. Even so, be aware that IRADIMED is showing 2 warning signs in our investment analysis, you should know about...